Short Interest in Oxford Biomedica plc (OTCMKTS:OXBDF) Rises By 73.4%

Oxford Biomedica plc (OTCMKTS:OXBDFGet Rating) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 13,700 shares, an increase of 73.4% from the March 15th total of 7,900 shares. Based on an average trading volume of 16,700 shares, the short-interest ratio is currently 0.8 days.

Shares of OTCMKTS OXBDF remained flat at $$8.50 during midday trading on Friday. 50 shares of the stock were exchanged, compared to its average volume of 5,505. The firm has a fifty day moving average of $9.16 and a 200 day moving average of $14.42. Oxford Biomedica has a fifty-two week low of $7.87 and a fifty-two week high of $22.86.

Separately, Zacks Investment Research upgraded shares of Oxford Biomedica from a “sell” rating to a “hold” rating in a report on Tuesday, February 15th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $24.00.

Oxford Biomedica Company Profile (Get Rating)

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes.

Featured Articles

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.